Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials (Q31127134)

29 June 2017

0 references

Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials (English)

1 reference

29 June 2017

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

1 reference

Fei Dai

1

1 reference

29 June 2017

Lixing Shu

2

1 reference

29 June 2017

Yangfang Bian

3

1 reference

29 June 2017

Zhuo Wang

4

1 reference

29 June 2017

Zhangwei Yang

5

1 reference

29 June 2017

Wengong Chu

6

1 reference

29 June 2017

Shen Gao

7

1 reference

29 June 2017

publication date

1 November 2013

1 reference

Clinical Drug Investigation

29 June 2017

published in

1 reference

29 June 2017

volume

33

1 reference

29 June 2017

issue

11

1 reference

29 June 2017

page(s)

779-788

1 reference

29 June 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Antiangiogenic drugs for colorectal cancer: exploring new possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0125-6

Some statistical methods for combining experimental results

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23979925

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23979925

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23979925

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40261-013-0125-6

1 reference

29 June 2017

1 reference